Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
暂无分享,去创建一个
R. Bataille | S. Colla | V. Rizzoli | N. Giuliani | R. Sala | G. Sammarelli | M. Lazzaretti | M. Moroni | S. Bonomini | S. La Monica | M. Hojden | S. Barillé | S. Barillé | Magda Hojden
[1] M. Matsuoka,et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. , 2002, Blood.
[2] O. Sezer,et al. Human bone marrow myeloma cells express RANKL. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Bataille,et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. , 2001, Blood.
[4] S. Khosla,et al. Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.
[5] R. Pacifici,et al. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Basten,et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. , 2001, Blood.
[7] T. Fry,et al. Interleukin-7: master regulator of peripheral T-cell homeostasis? , 2001, Trends in immunology.
[8] J. Michaeli,et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[9] F. Dammacco,et al. Deregulated cytokine network and defective Th1 immune response in multiple myeloma , 2001, Clinical and experimental immunology.
[10] N. Kamatani,et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. , 2001, Arthritis and rheumatism.
[11] J. Haug,et al. T Cell Activation Induces Human Osteoclast Formation via Receptor Activator of Nuclear Factor κB Ligand‐Dependent and ‐Independent Mechanisms , 2001 .
[12] Yufang Shi,et al. Differential Regulation of the Expression of CD95 Ligand, Receptor Activator of Nuclear Factor-κB Ligand (RANKL), TNF-Related Apoptosis-Inducing Ligand (TRAIL), and TNF-α During T Cell Activation1 2 , 2001, The Journal of Immunology.
[13] S. Hsieh,et al. Enhanced Secretion of IFN-γ by Activated Th1 Cells Occurs Via Reverse Signaling Through TNF-Related Activation-Induced Cytokine1 , 2001, The Journal of Immunology.
[14] X. Luo,et al. Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappa B ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation. , 2001, Journal of immunology.
[15] J. Haug,et al. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] Hiroshi Takayanagi,et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.
[17] Yongwon Choi,et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Penninger,et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. , 2000, The Journal of clinical investigation.
[19] C. Dinarello. Interleukin-18, a proinflammatory cytokine. , 2000, European cytokine network.
[20] R. Pacifici,et al. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. , 2000, Blood.
[21] D. Joshua,et al. T‐cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells , 2000, British journal of haematology.
[22] C. Franceschi,et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. , 2000, Blood.
[23] Banning,et al. Transforming Growth Factor‐β1 Suppresses Interleukin‐15‐Mediated Interferon‐γ Production in Human T Lymphocytes , 1999, Scandinavian journal of immunology.
[24] G. Cook,et al. Transforming growth factor β from multiple myeloma cells inhibits proliferation and IL‐2 responsiveness in T lymphocytes , 1999, Journal of leukocyte biology.
[25] Josef M. Penninger,et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.
[26] R. Steinman,et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. , 1999, Journal of immunology.
[27] D. Lacey,et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors , 1999, Journal of cellular biochemistry.
[28] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[29] R. Bataille,et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. , 1997, Blood.
[30] R. Bataille,et al. Pathogenesis and management of bone lesions in multiple myeloma. , 1997, Hematology/oncology clinics of North America.
[31] J. Haug,et al. Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] P. Moss,et al. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. , 1996, Blood.
[33] D. Postma,et al. IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms. , 1996, Journal of immunology.
[34] J. S. San Miguel,et al. Increased production of interleukin-6 by T lymphocytes from patients with multiple myeloma. , 1996, Experimental Hematology.
[35] N. Mukaida,et al. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state. , 1995, Journal of immunology.
[36] M. Jourdan,et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.
[37] O. Majdic,et al. Transforming growth factor-β inhibits IL-4 and IFN-γ production by stimulated human T cells , 1994 .
[38] O. Majdic,et al. Transforming growth factor-beta inhibits IL-4 and IFN-gamma production by stimulated human T cells. , 1994, International immunology.
[39] B. Klein,et al. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro , 1993 .
[40] M. Feldmann,et al. T cells and lymphokines. , 1989, British medical bulletin.
[41] B. Sander,et al. Concomitant production of different lymphokines in activated T cells , 1988, European journal of immunology.
[42] A. Palumbo,et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. , 1988, Blood.